Group 1 - LRT Capital Management's "LRT Global Opportunities Strategy" reported a net return of -8.00% in September 2025, with a year-to-date return of -0.17% [1] - The strategy faced challenges as market indexes surged, particularly driven by a few overvalued mega-cap stocks, while the broader market declined [1] - The fund's top five holdings were highlighted as key picks for 2025 [1] Group 2 - Chemed Corporation (NYSE:CHE) is noted for its unique structure, operating in two non-correlated sectors: hospice care through VITAS and plumbing services through Roto-Rooter [3] - Chemed Corporation's one-month return was 5.91%, but it experienced a significant decline of 25.88% over the past 52 weeks [2] - As of October 6, 2025, Chemed Corporation's stock closed at $435.38 per share, with a market capitalization of $6.344 billion [2]

Core Insights - Addus HomeCare reported strong Q2 2025 financial results, with revenue and earnings exceeding Wall Street estimates, driven by organic growth and acquisitions [1][2] Financial Performance - Q2 2025 GAAP revenue was $349.4 million, surpassing the estimate of $346.5 million, and reflecting a 21.8% increase from Q2 2024 [2] - Non-GAAP earnings per share reached $1.49, exceeding the consensus of $1.47 and marking a 10.4% year-over-year growth [2] - Adjusted EBITDA was $43.9 million, up 24.4% from $35.3 million in Q2 2024 [2] - Net income increased to $22.1 million, a 22.1% rise from $18.1 million in the previous year [2] - Cash flow from operations was $22.5 million, a 19.7% increase from $18.8 million in Q2 2024 [2] Business Overview - Addus HomeCare operates in 23 states, focusing on personal care, hospice care, and home health services [3] - Personal care services account for 77% of total revenue, with a year-over-year growth of 26.5% [5] - Hospice services contributed 17.8% of revenue, showing a 10.0% organic growth rate [6] - Home health services represented 5.2% of overall revenue, with a slight decline year-over-year [7] Strategic Initiatives - The company aims for organic growth through increased service volumes and rates, alongside strategic acquisitions [4] - Recent acquisitions, including Gentiva Personal Care Services, have enhanced market coverage and service density [5][8] - Technology adoption is progressing, with a caregiver scheduling app being rolled out to improve operational efficiency [8] Market Outlook - The company anticipates robust demand for home-based care and continues to focus on operational efficiency and accretive acquisitions [9] - Organic revenue growth in Personal Care exceeded the long-term target range of 3-5% [9] - Management is closely monitoring government reimbursement rates and regulatory developments, as most revenue is derived from Medicaid and Medicare [10]

Core Insights - Amedisys reported strong quarterly earnings, exceeding market expectations for both revenue and adjusted profitability despite merger-related costs impacting GAAP results [1][5] - GAAP revenue reached $621.9 million, surpassing the consensus estimate of $611.99 million, while Non-GAAP EPS was $1.54, exceeding the forecast of $1.36 [1][2] Financial Performance - GAAP revenue grew by 5.2% year-over-year from $591.2 million in Q2 2024 [2][5] - Adjusted EBITDA increased by 10.4% compared to Q2 2024, indicating improved operational efficiency [2][5] - Non-GAAP net income rose to $51.4 million from $43.5 million in Q2 2024, reflecting strong core operations [5] - GAAP net income fell to $28.1 million, a decrease of 13% from $32.3 million in Q2 2024, primarily due to $26.3 million in merger-related expenses [2][6] Operational Highlights - Amedisys operates a national network of 519 care centers, serving nearly half a million patients annually across 38 states and Washington, D.C. [3] - The company focuses on regulatory compliance, high-quality clinical care, and strategic partnerships, with approximately 70-74% of revenue derived from Medicare [4] - The average home health quality rating is 4.18 out of 5 stars, indicating a commitment to clinical excellence [4] Cash Flow and Collections - The "days revenue outstanding" metric improved significantly, dropping to 40.9 days from 52.1 days in Q2 2024, indicating faster payment collections [7] - Cash from operations increased to $67.2 million compared to $52.3 million in Q2 2024, with ending cash and equivalents at $337.3 million as of June 30, 2025 [7] Future Outlook - Company leadership did not provide forward financial guidance for the upcoming quarter or fiscal 2025 due to the pending merger with UnitedHealth Group [9] - Significant regulatory and completion risks associated with the merger were highlighted, impacting future growth prospects [9][10]

Core Insights - Chemed missed expectations on both revenue and earnings for Q2, leading to a 9% decline in share price [1] - The company reported a 4% increase in sales but a significant 22% drop in adjusted earnings per share (EPS) [2] - Management has lowered the 2025 EPS guidance from $25.20 to $22.15, indicating a 4% decline from the previous year [2] - CEO of Vitas Healthcare, Nick Westfall, announced his resignation, adding to the uncertainty surrounding the company [2] Revenue and Profitability - Chemed's Q2 revenue growth was steady at 4%, but profitability issues were evident across all business segments [3] - Vitas Healthcare experienced a 4% revenue growth but faced Medicare cap billing limitations, resulting in a 24% decline in earnings [4] - Excluding one-time impacts, Vitas's adjusted EBITDA remained flat for the quarter [4] Roto-Rooter Performance - Roto-Rooter, Chemed's plumbing business, achieved only 1% sales growth while net income fell by 20% due to increased marketing costs [6] - The company faces challenges from advertising pressures, particularly from Google, which affects visibility in free search areas [6] - Despite these challenges, Roto-Rooter remains the largest plumbing company in North America, warranting investor attention [7] Future Outlook - Chemed is currently navigating several challenges but is valued at 20 times free cash flow, suggesting potential for a turnaround [7]